the main ingredient in Ozempic and Wegovy, have led to at least 100 hospitalizations and 10 deaths. CEO Lars Fruergaard ...

Novo Nordisk reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its shares up nearly 9%.

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Ngo mentions that availability of Wegovy could be difficult because the drug is so popular. “Supply chain issues may arise from time to time. Novo Nordisk is actively working to ramp up ...

Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 ...

After years in shortage, weight loss and diabetes drugs Ozempic and Wegovy are now considered to be “available” by the Food ...

Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...

Since Wegovy is a prescription medication, your insurance coverage may affect your ability to get the drug at an affordable cost. The status of the supply chain can also determine how accessible ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...